

VASTox plc
(“VASTox” or “the Company”)

Results of Annual General Meeting

Oxford, UK, 19 July 2007 – VASTox plc (AIM: VOX), a leading UK biotechnology company, announces that at today’s Annual General Meeting all resolutions, including two special resolutions, were passed.

- The Company will change its name from VASTox plc to Summit Corporation plc (“Summit plc”) and with effect from the 20 of July 2007, the Company’s new trading ticker on AIM will be “SUMM”.
- The Board has been granted authority to issue for new shares up to a nominal value of £1,000,000.
- The following Directors were all re-elected to the Board of Directors: Sir Brian Richards, James Taylor, Barry Price, Colin Wall, Andrew Richards, George Elliott, Stephen Davies and David Norwood.
- The Reports of the Directors and Auditors and the Accounts for the year ended 31 January 2007 were approved. BDO Stoy Hayward LLP was also reappointed as the Auditors of the Company.

- ends -

For more information please contact:

VASTox

Steven Lee, PhD, Chief Executive Officer
Darren Millington, ACMA, Chief Financial Officer

Tel: +44 (0)1235 443951

Citigate Dewe Rogerson

Mark Swallow / David Dible / Valerie Auffray

Tel: +44 (0)207 638 9571

Evolution Securities

Tim Worlledge / Bobbie Hilliam / Neil Elliot

Tel: +44 (0)207 071 4300

About VASTox plc

VASTox is a leading UK biotechnology company that discovers and develops proprietary new drugs. The Company’s internal drug development programmes are underpinned by its advanced chemistry and drug screening (chemical genomics) technology platforms, which it also provides on a collaborative or fee-for-service basis to the pharmaceutical industry.

VASTox has a broad range of drug discovery programmes in the clinical, pre-clinical and discovery stages of development, which target serious diseases with a high unmet medical need. These therapeutic areas include neuro-disorders (neurodegenerative and neuromuscular), anti-infectives, ophthalmic diseases, oncology and regenerative medicines.

VASTox's in-house drug development capabilities combine world-class expertise in both medicinal and carbohydrate chemistry with high-volume, high-content screening using its proprietary zebrafish and fruitfly technologies (chemical genomics). These whole organism screens have the potential to dramatically decrease the time and cost of drug discovery and development by delivering data that are highly predictive of the efficacy and toxicity of potential drug compounds in humans.

The company listed on the AIM market of the London Stock Exchange in October 2004 – symbol: VOX

Further information about the company is available at www.vastox.com

This document contains "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "anticipates", "intends", "plans", "seeks", "believes", "estimates", "expects" and similar references to future periods, or by the inclusion of forecasts or projections.

Forward-looking statements are based on the Company's current expectations and assumptions regarding our business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. The Company's actual results may differ materially from those contemplated by the forward-looking statements. The Company cautions you therefore that you should not rely on any of these forward-looking statements as statements of historical fact or as guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements and regional, national, global political, economic, business, competitive, market and regulatory conditions.